Cite
HARVARD Citation
Liu, L. et al. (2016). Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma. Journal of hematology & oncology. 9 (1), pp. 1-7. [Online].